People diagnosed with DM are approximately 20% more likely to suffer from anxiety than those without diabetes. Metformin is the first line therapy for treating T2DM, whereas pregabalin is the first line therapy for treating diabetic neuropathy as well as generalized anx-iety disorder (GAD). The objective of this study was to investigate the effect of combining pregabalin with met-formin in patients who suffer from anxiety and see to what extent does it reduce anxiety symptoms as well as their glycated hemoglobin level. Related data were col-lected from T2DM individuals that were undergoing treatment with metformin alone and those with met-formin and pregabalin combination. A greater decre-ment in anxiety symptoms and HbA1c occurred in pa-tients taking the combination therapy. Besides pregaba-lin’s use to decrease neuropathy symptoms it can also alleviate anxiety symptoms in diabetic patients bringing about a better glycemic control in them.

Key words: Type 1 diabetes, Type 2 diabetes, Metformin, pregabalin.

DOI: http://doi.org/10.24086/biohs2022/paper.642